Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of monalizumab after haploidentical stem cell transplantation with post-transplant cyclophosphamide in AML or MDS
2020-005902-24Phase 2Active
- Sponsor
- Humanitas Research Hospital
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monalizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Humanitas Research Hospital. Primary endpoint: Graft-versus-host disease-free, relapse-free survival. Started Jun 2021; status: active.
02
Drugs
monalizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-005902-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005902-24.